Oppenheimer & CO Inc Bio N Tech Se Transaction History

Oppenheimer & CO Inc

  • $6.42 Billion
  • Q3 2024

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024
SELL
$90.91 - $112.75 $279,820 - $347,044
-3,078 Reduced 45.56%
3,678 $388,000
Q3 2023

Nov 07, 2023
SELL
$98.5 - $125.08 $199,068 - $252,786
-2,021 Reduced 23.03%
6,756 $733,000
Q2 2023

Aug 02, 2023
SELL
$102.58 - $129.66 $157,460 - $199,028
-1,535 Reduced 14.89%
8,777 $947,000
Q1 2023

May 10, 2023
SELL
$122.57 - $153.67 $754,418 - $945,838
-6,155 Reduced 37.38%
10,312 $1.28 Million
Q4 2022

Feb 07, 2023
BUY
$118.43 - $186.05 $459,153 - $721,315
3,877 Added 30.79%
16,467 $2.47 Million
Q3 2022

Nov 14, 2022
BUY
$127.65 - $183.11 $17,488 - $25,086
137 Added 1.1%
12,590 $1.7 Million
Q2 2022

Aug 08, 2022
SELL
$123.25 - $186.24 $95,149 - $143,777
-772 Reduced 5.84%
12,453 $1.86 Million
Q1 2022

May 12, 2022
SELL
$126.25 - $231.85 $412,458 - $757,453
-3,267 Reduced 19.81%
13,225 $2.26 Million
Q4 2021

Feb 02, 2022
BUY
$216.64 - $362.52 $5,632 - $9,425
26 Added 0.16%
16,492 $4.25 Million
Q3 2021

Nov 12, 2021
SELL
$205.93 - $447.23 $351,934 - $764,316
-1,709 Reduced 9.4%
16,466 $4.5 Million
Q2 2021

Aug 03, 2021
BUY
$113.32 - $241.49 $585,637 - $1.25 Million
5,168 Added 39.73%
18,175 $4.07 Million
Q1 2021

May 10, 2021
BUY
$85.73 - $119.5 $1.12 Million - $1.55 Million
13,007 New
13,007 $1.42 Million

Others Institutions Holding BNTX

# of Institutions
358
Shares Held
38.4M
Call Options Held
2.45M
Put Options Held
2.29M
View Full List

About BioNTech SE

BNTX Quotes by TradingView
  • Ticker BNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 242,684,992
  • Market Cap $24.2B
  • Description
  • BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...
More about BNTX
Track This Portfolio

Track Oppenheimer & CO Inc Portfolio

Follow Oppenheimer & CO Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

News

Stay updated on Oppenheimer & CO Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email